Daniel Shaughnessy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Daniel Shaughnessy has a total of 17 co-authors. Here are the top co-authors by number of shared publications:
Tianjing Li
6 shared publicationsAaron Beckwith
4 shared publications- Ashma Krishan
Centre for Biostatistics, University of Manchester, Manchester, UK
4 shared publications - Kevin Naaman
Department of Ophthalmology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA
4 shared publications - Riaz Qureshi
University of Colorado Anschutz Medical Campus
4 shared publications Louis Leslie
Anschutz Medical Campus University of Colorado Aurora Colorado USA
2 shared publications
Latest Publications
- Open Access
- 23 September 2026
- Published by Elsevier in Journal of Clinical Epidemiology
Harms were rarely specified or reported in public health randomized trials: a meta-epidemiological study
- 23 September 2026
- Published by Elsevier in Journal of Clinical Epidemiology
Open AccessHarms were rarely specified or reported in public health randomized trials: a meta-epidemiological study
- Open Access
- 4 July 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 198, 112401
Harms Reporting Was Frequently Incomplete or Discordant in Biomedical Randomized Trials Published in 2023: A Meta-epidemiological Study
- 4 July 2026
- Published by Elsevier in Journal of Clinical Epidemiology
- Vol. 198, 112401
Open AccessHarms Reporting Was Frequently Incomplete or Discordant in Biomedical Randomized Trials Published in 2023: A Meta-epidemiological Study
- Open Access
- 16 May 2026
- Published by Wiley in Cochrane Evidence Synthesis and Methods
- Vol. 4 (3) , e70081
Influence of Social and Demographic Factors on Retinoblastoma Outcomes in the United States: A Systematic Review
Introduction: Social determinants of health (SDOH), which include economic stability, education access and quality, community and social context, healthcare access and quality, and neighborhood and built environment, are known to be related to variation in health outcomes across a variety of health conditions. Ocular neoplasms are among the health conditions that have been shown to be affected by SDOH, and retinoblastoma is the most prevalent form in children. Our objective was to systematically review documented associations between SDOH and retinoblastoma in the US. Methods: We followed a pre‐established protocol. We searched Medline, Embase, and Web of Science from 2000 to November 2023 using a mix of keywords and controlled vocabulary. We included primary studies of any design that evaluated one or more relationships between SDOH and retinoblastoma outcomes, such as survival, mortality, disease staging, types of care, and incidence. We extracted data on study design, population characteristics, SDOH domains and indicators, and estimates of associations with retinoblastoma outcomes. We assessed risk of bias using a modified Newcastle‐Ottawa Scale and performed narrative syntheses. Results: We included 26 studies that had reported a total of 552 associations. Social and community context, notably race and ethnicity, was the most commonly examined domain, suggesting evidence of worse survival outcomes for Black and Hispanic patients. The most clinically and policy‐relevant patterns were concentrated in social and community context, economic stability, and healthcare access and quality SDOH domains, where measures such as race and ethnicity, poverty, unemployment, and insurance status were repeatedly associated with stage at diagnosis, enucleation, and survival. Conclusion: SDOH were frequently associated with retinoblastoma diagnosis, treatment, and survival in US studies. The most clinically relevant findings relate to insurance‐related access barriers, socioeconomic disadvantage, and social and community factors, while environmental and occupational exposures were more informative for disease cause and prevention. Our findings underscore the need for more consistent SDOH measurement and adjustment methods to improve study comparability and to inform targeted interventions to address retinoblastoma health outcomes.
- 16 May 2026
- Published by Wiley in Cochrane Evidence Synthesis and Methods
- Vol. 4 (3) , e70081
Open AccessInfluence of Social and Demographic Factors on Retinoblastoma Outcomes in the United States: A Systematic Review
Introduction: Social determinants of health (SDOH), which include economic stability, education access and quality, community and social context, healthcare access and quality, and neighborhood and built environment, are known to be related to variation in health outcomes across a variety of health conditions. Ocular neoplasms are among the health conditions that have been shown to be affected by SDOH, and retinoblastoma is the most prevalent form in children. Our objective was to systematically review documented associations between SDOH and retinoblastoma in the US. Methods: We followed a pre‐established protocol. We searched Medline, Embase, and Web of Science from 2000 to November 2023 using a mix of keywords and controlled vocabulary. We included primary studies of any design that evaluated one or more relationships between SDOH and retinoblastoma outcomes, such as survival, mortality, disease staging, types of care, and incidence. We extracted data on study design, population characteristics, SDOH domains and indicators, and estimates of associations with retinoblastoma outcomes. We assessed risk of bias using a modified Newcastle‐Ottawa Scale and performed narrative syntheses. Results: We included 26 studies that had reported a total of 552 associations. Social and community context, notably race and ethnicity, was the most commonly examined domain, suggesting evidence of worse survival outcomes for Black and Hispanic patients. The most clinically and policy‐relevant patterns were concentrated in social and community context, economic stability, and healthcare access and quality SDOH domains, where measures such as race and ethnicity, poverty, unemployment, and insurance status were repeatedly associated with stage at diagnosis, enucleation, and survival. Conclusion: SDOH were frequently associated with retinoblastoma diagnosis, treatment, and survival in US studies. The most clinically relevant findings relate to insurance‐related access barriers, socioeconomic disadvantage, and social and community factors, while environmental and occupational exposures were more informative for disease cause and prevention. Our findings underscore the need for more consistent SDOH measurement and adjustment methods to improve study comparability and to inform targeted interventions to address retinoblastoma health outcomes.
- Open Access
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
Assessment and Reporting of Harms in Randomized Controlled Trials: A Meta-Epidemiological Study on Trials of Public Health Interventions Published in 2023
BackgroundPublic health interventions can produce adverse and unintended consequences (i.e., harms), but it is unclear how consistently randomized controlled trials (RCTs) of public health interventions plan for and report harms. Incomplete or selective harms reporting can undermine interpretation and evidence synthesis.MethodsWe conducted a meta-epidemiological study of 100 RCTs of public health interventions whose primary full-text report was indexed in PubMed in 2023. Using the publication and publicly linked documents (registrations, protocols, supplements), we assessed harms specification, harms reporting, concordance, transparency of reporting criteria, and whether reported harms were grouped by PROGRESS-Plus equity-related factors.ResultsOnly 25% (25/100) specified at least one harm, and 23% (23/100) reported any harms, while 72% (72/100) neither specified nor reported harms. Among 28 trials that mentioned harms, 12 (43%) reported all specified harms, 8 (29%) reported only a subset, and 8 (29%) showed other discordance. No trial specified harms reporting criteria, and none reported harms using identifiable criteria. Trials with a registry listing and those with an identified protocol had higher odds of harms specification compared with trials without a registry or protocol (OR = 4.7 [1.5, 14.3] and OR = 3.9 [1.5, 10.1], respectively); trials with pharmacological interventions also showed higher odds of specification compared with other intervention types (OR = 9.8 [1.9, 49.9]). Similarly, harms reporting was higher in trials with a registry or protocol (OR = 4.0 [1.3, 12.4] and OR = 3.8 [1.4, 10.0], respectively). Although 89% of trial reports considered at least one PROGRESS-Plus factor among participant characteristics, none reported harms stratified by these factors. Compared with a parallel biomedical sample, public health trials specified and reported harms far less often.ConclusionsIn our sample of RCTs of public health interventions, most trials did not specify harms they planned to measure and did not report harms results. To make public health RCTs more useful in evidence syntheses and decision-making, investigators should specify plausible harms upfront in registries and protocols, then report results for all recorded harms consistently across reports and registries. When harms may differ across groups, reported harms should also be grouped by equity-related participant characteristics.
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAssessment and Reporting of Harms in Randomized Controlled Trials: A Meta-Epidemiological Study on Trials of Public Health Interventions Published in 2023
BackgroundPublic health interventions can produce adverse and unintended consequences (i.e., harms), but it is unclear how consistently randomized controlled trials (RCTs) of public health interventions plan for and report harms. Incomplete or selective harms reporting can undermine interpretation and evidence synthesis.MethodsWe conducted a meta-epidemiological study of 100 RCTs of public health interventions whose primary full-text report was indexed in PubMed in 2023. Using the publication and publicly linked documents (registrations, protocols, supplements), we assessed harms specification, harms reporting, concordance, transparency of reporting criteria, and whether reported harms were grouped by PROGRESS-Plus equity-related factors.ResultsOnly 25% (25/100) specified at least one harm, and 23% (23/100) reported any harms, while 72% (72/100) neither specified nor reported harms. Among 28 trials that mentioned harms, 12 (43%) reported all specified harms, 8 (29%) reported only a subset, and 8 (29%) showed other discordance. No trial specified harms reporting criteria, and none reported harms using identifiable criteria. Trials with a registry listing and those with an identified protocol had higher odds of harms specification compared with trials without a registry or protocol (OR = 4.7 [1.5, 14.3] and OR = 3.9 [1.5, 10.1], respectively); trials with pharmacological interventions also showed higher odds of specification compared with other intervention types (OR = 9.8 [1.9, 49.9]). Similarly, harms reporting was higher in trials with a registry or protocol (OR = 4.0 [1.3, 12.4] and OR = 3.8 [1.4, 10.0], respectively). Although 89% of trial reports considered at least one PROGRESS-Plus factor among participant characteristics, none reported harms stratified by these factors. Compared with a parallel biomedical sample, public health trials specified and reported harms far less often.ConclusionsIn our sample of RCTs of public health interventions, most trials did not specify harms they planned to measure and did not report harms results. To make public health RCTs more useful in evidence syntheses and decision-making, investigators should specify plausible harms upfront in registries and protocols, then report results for all recorded harms consistently across reports and registries. When harms may differ across groups, reported harms should also be grouped by equity-related participant characteristics.
- Open Access
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
Assessment and Reporting of Harms in Randomized Controlled Trials: A Meta-Epidemiological Study on Trials of Biomedical Interventions Published in 2023
BackgroundDecisions about biomedical interventions require clear evidence on benefits and harms, yet harms are often evaluated and reported less rigorously than efficacy outcomes. Unstated reporting rules for harms may lead to "cherry-picked" results in primary studies.MethodsWe conducted a meta-epidemiological study of a random sample of 200 randomized controlled trials (RCTs) of biomedical interventions indexed in PubMed in 2023. Using publicly available protocols, trial registries, and publications, we assessed harms specification, harms reporting, concordance between specified and reported harms, transparency about harms reporting criteria, and whether trials had considered PROGRESS-Plus equity-related factors (an equity framework for participant characteristics linked to health inequities) in reporting harms.ResultsSixty-four percent (128/200) of trials were registered and 15.5% had an accessible protocol (31/200). Harms were specified in 64.0% (128/200) of primary publications and reported in 69.5% (139/200). Concordance was often incomplete: 43.5% (87/200) reported all specified harms, and 26.5% (53/200) specified no harms and reported none, while 14.5% (29/200) reported only some specified harms, and 15.5% (31/200) showed other discordance. Only 1.0% (2/200) clearly specified harms reporting criteria, and 7.0% (14/200) indicated using criteria when reporting. Trials with a registry listing or an identified protocol had higher odds of specifying harms compared with trials without a registry listing or an identified protocol (OR = 2.1 [1.2, 3.8] and OR = 5.6 [1.8, 18.1], respectively). Compared with behavioral or physical therapy interventions, pharmaceutical, surgical, or device trials had higher odds of harms specification (OR = 5.3 [2.8, 10.1]) and harms reporting (OR = 6.8 [3.5, 13.2]). No trials reported harms stratified by PROGRESS-Plus equity-related factors.ConclusionsIn a contemporary sample of biomedical RCTs, harms were frequently specified and reported, but concordance between planned and reported harms and transparency about reporting criteria remain deficient. Trialists should pre-specify harms outcomes in protocols/registrations and report harms comprehensively and consistently across all public sources; descriptive harms summaries by key equity-related factors should be used to help identify potential vulnerability. Journal editors and peer reviewers should require clearer harms methods and complete harms results in RCT reports.
- 12 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAssessment and Reporting of Harms in Randomized Controlled Trials: A Meta-Epidemiological Study on Trials of Biomedical Interventions Published in 2023
BackgroundDecisions about biomedical interventions require clear evidence on benefits and harms, yet harms are often evaluated and reported less rigorously than efficacy outcomes. Unstated reporting rules for harms may lead to "cherry-picked" results in primary studies.MethodsWe conducted a meta-epidemiological study of a random sample of 200 randomized controlled trials (RCTs) of biomedical interventions indexed in PubMed in 2023. Using publicly available protocols, trial registries, and publications, we assessed harms specification, harms reporting, concordance between specified and reported harms, transparency about harms reporting criteria, and whether trials had considered PROGRESS-Plus equity-related factors (an equity framework for participant characteristics linked to health inequities) in reporting harms.ResultsSixty-four percent (128/200) of trials were registered and 15.5% had an accessible protocol (31/200). Harms were specified in 64.0% (128/200) of primary publications and reported in 69.5% (139/200). Concordance was often incomplete: 43.5% (87/200) reported all specified harms, and 26.5% (53/200) specified no harms and reported none, while 14.5% (29/200) reported only some specified harms, and 15.5% (31/200) showed other discordance. Only 1.0% (2/200) clearly specified harms reporting criteria, and 7.0% (14/200) indicated using criteria when reporting. Trials with a registry listing or an identified protocol had higher odds of specifying harms compared with trials without a registry listing or an identified protocol (OR = 2.1 [1.2, 3.8] and OR = 5.6 [1.8, 18.1], respectively). Compared with behavioral or physical therapy interventions, pharmaceutical, surgical, or device trials had higher odds of harms specification (OR = 5.3 [2.8, 10.1]) and harms reporting (OR = 6.8 [3.5, 13.2]). No trials reported harms stratified by PROGRESS-Plus equity-related factors.ConclusionsIn a contemporary sample of biomedical RCTs, harms were frequently specified and reported, but concordance between planned and reported harms and transparency about reporting criteria remain deficient. Trialists should pre-specify harms outcomes in protocols/registrations and report harms comprehensively and consistently across all public sources; descriptive harms summaries by key equity-related factors should be used to help identify potential vulnerability. Journal editors and peer reviewers should require clearer harms methods and complete harms results in RCT reports.
- Open Access
- 10 March 2026
- Published by Wiley in Cochrane Evidence Synthesis and Methods
- Vol. 4 (2)
Associations of Social and Demographic Factors on the Outcomes of Ocular Melanoma and Other Adult Ocular Neoplasms in the United States: A Systematic Review
Introduction: Social determinants of health (SDOH), including economic stability, education access and quality, healthcare access and quality, neighborhood and built environment, and social and community context, shape gaps in health outcomes across many conditions. Ocular neoplasms are no exception. Cancers such as uveal melanoma, conjunctival squamous cell carcinoma, ocular lymphoma, and ocular Kaposi sarcoma may be especially vulnerable to social and demographic influences. We systematically reviewed documented associations between SDOH and these ocular cancers in the United States. Methods: Following a pre‐registered protocol, we searched MEDLINE, Embase, and Web of Science (from January 2000 to November 2023) for primary studies of any design that evaluated one or more relationships between SDOH and outcomes related to the ocular cancers listed above. Outcomes included cancer incidence, stage at diagnosis, treatment patterns, survival, and mortality. We extracted study design, population, exposure, and outcome characteristics, classified each exposure‐outcome association by its direction (e.g., favorable, unfavorable, or null), and assessed the risk of bias using a modified Newcastle‐Ottawa Scale. Due to heterogeneity in exposure and outcome definitions, we narratively synthesized findings by SDOH domain. Results: We included 21 studies examining 167 unique associations. Social and community context, typically represented as race and ethnicity, was the most frequently studied domain, followed by economic stability (e.g., income) and healthcare access and quality (e.g., insurance type or travel distance). Across domains, lower socioeconomic status, public or no insurance, minority racial and ethnic identity, and care at academic centers generally are associated with later stage at diagnosis, higher odds of enucleation, or worse survival. Higher income, private insurance, and treatment at experienced facilities were often associated to earlier presentation and better outcomes. Conclusion: SDOH have a measurable and often unfavorable relationship with the diagnosis, management, and prognosis of rare adult ocular cancers in the United States. Standardized SDOH exposures and measurements, prospective data collection, and adjustment for confounding are necessary to strengthen the evidence and guide multi‐domain interventions (e.g., expanded insurance, travel assistance to high‐volume centers, and community eye‐health initiatives) aimed at narrowing these gaps.
- 10 March 2026
- Published by Wiley in Cochrane Evidence Synthesis and Methods
- Vol. 4 (2)
Open AccessAssociations of Social and Demographic Factors on the Outcomes of Ocular Melanoma and Other Adult Ocular Neoplasms in the United States: A Systematic Review
Introduction: Social determinants of health (SDOH), including economic stability, education access and quality, healthcare access and quality, neighborhood and built environment, and social and community context, shape gaps in health outcomes across many conditions. Ocular neoplasms are no exception. Cancers such as uveal melanoma, conjunctival squamous cell carcinoma, ocular lymphoma, and ocular Kaposi sarcoma may be especially vulnerable to social and demographic influences. We systematically reviewed documented associations between SDOH and these ocular cancers in the United States. Methods: Following a pre‐registered protocol, we searched MEDLINE, Embase, and Web of Science (from January 2000 to November 2023) for primary studies of any design that evaluated one or more relationships between SDOH and outcomes related to the ocular cancers listed above. Outcomes included cancer incidence, stage at diagnosis, treatment patterns, survival, and mortality. We extracted study design, population, exposure, and outcome characteristics, classified each exposure‐outcome association by its direction (e.g., favorable, unfavorable, or null), and assessed the risk of bias using a modified Newcastle‐Ottawa Scale. Due to heterogeneity in exposure and outcome definitions, we narratively synthesized findings by SDOH domain. Results: We included 21 studies examining 167 unique associations. Social and community context, typically represented as race and ethnicity, was the most frequently studied domain, followed by economic stability (e.g., income) and healthcare access and quality (e.g., insurance type or travel distance). Across domains, lower socioeconomic status, public or no insurance, minority racial and ethnic identity, and care at academic centers generally are associated with later stage at diagnosis, higher odds of enucleation, or worse survival. Higher income, private insurance, and treatment at experienced facilities were often associated to earlier presentation and better outcomes. Conclusion: SDOH have a measurable and often unfavorable relationship with the diagnosis, management, and prognosis of rare adult ocular cancers in the United States. Standardized SDOH exposures and measurements, prospective data collection, and adjustment for confounding are necessary to strengthen the evidence and guide multi‐domain interventions (e.g., expanded insurance, travel assistance to high‐volume centers, and community eye‐health initiatives) aimed at narrowing these gaps.
- 5 July 2021
- Published by Wiley in Hemodialysis International
- Vol. 26 (1) , 114-123
Does experience matter? The relationship between nephrologist characteristics and end stage kidney disease patient outcomes
Background Nephrology offers the unique opportunity to directly link patients to providers, allowing the study of patient outcomes at the provider level. The purpose of this analysis was to determine whether nephrologist experience, defined as years in nephrology practice, was associated with clinical outcomes. Design Physician data contained within the American Medical Association (AMA) Physician Masterfile was combined with patient and Medicare claims data from the United States Renal Data System (USRDS) for the calendar year 2012, with follow up extending through June 30, 2014. Associations with important healthcare outcomes including mortality in patients receiving maintenance renal replacement therapy (RRT), waitlisting for kidney transplantation, and receipt of a kidney transplant were determined with broad adjustment for both patient and provider level variables, with attention on tertile of provider time in practice. Results We identified 256,324 patients on maintenance RRT cared for by 6193 nephrologists. Nephrologists with the least experience were more likely to be female, reside in a region with >= 1,000,000 people, have a Doctor of Osteopathic Medicine degree, and have a listed maintenance of certification status as "yes." Overall, 30.2% of the cohort died at a mean follow up of 1.99 years. Compared to those with the 0-10 years of experience, receipt of care from nephrologists with more experience was associated with lower mortality (AHR 0.97 CI 0.94-0.99 for nephrologists with 11-20 years) and increased listing for kidney transplantation (AHR 1.10; CI 1.01-1.21 for nephrologists with >21 years experience). Experience level did not result in a difference in kidney transplantation rates. Conclusions Receipt of maintenance RRT from nephrologists with greater experience was associated with decreased mortality and increased listing for kidney transplantation, an effect that remained significant after multiple adjustments for important patient and nephrologist variables.
- 5 July 2021
- Published by Wiley in Hemodialysis International
- Vol. 26 (1) , 114-123
Does experience matter? The relationship between nephrologist characteristics and end stage kidney disease patient outcomes
Background Nephrology offers the unique opportunity to directly link patients to providers, allowing the study of patient outcomes at the provider level. The purpose of this analysis was to determine whether nephrologist experience, defined as years in nephrology practice, was associated with clinical outcomes. Design Physician data contained within the American Medical Association (AMA) Physician Masterfile was combined with patient and Medicare claims data from the United States Renal Data System (USRDS) for the calendar year 2012, with follow up extending through June 30, 2014. Associations with important healthcare outcomes including mortality in patients receiving maintenance renal replacement therapy (RRT), waitlisting for kidney transplantation, and receipt of a kidney transplant were determined with broad adjustment for both patient and provider level variables, with attention on tertile of provider time in practice. Results We identified 256,324 patients on maintenance RRT cared for by 6193 nephrologists. Nephrologists with the least experience were more likely to be female, reside in a region with >= 1,000,000 people, have a Doctor of Osteopathic Medicine degree, and have a listed maintenance of certification status as "yes." Overall, 30.2% of the cohort died at a mean follow up of 1.99 years. Compared to those with the 0-10 years of experience, receipt of care from nephrologists with more experience was associated with lower mortality (AHR 0.97 CI 0.94-0.99 for nephrologists with 11-20 years) and increased listing for kidney transplantation (AHR 1.10; CI 1.01-1.21 for nephrologists with >21 years experience). Experience level did not result in a difference in kidney transplantation rates. Conclusions Receipt of maintenance RRT from nephrologists with greater experience was associated with decreased mortality and increased listing for kidney transplantation, an effect that remained significant after multiple adjustments for important patient and nephrologist variables.